- Home
- SNGX vs ONFO Comparison
SNGX vs ONFO Comparison
Compare SNGX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- ONFO
- Stock Information
- Founded
- SNGX 1987
- ONFO 2018
- Country
- SNGX United States
- ONFO United States
- Employees
- SNGX N/A
- ONFO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- SNGX Health Care
- ONFO Technology
- Exchange
- SNGX Nasdaq
- ONFO Nasdaq
- Market Cap
- SNGX 10.1M
- ONFO 5.0M
- IPO Year
- SNGX 1987
- ONFO 2022
- Fundamental
- Price
- SNGX $2.81
- ONFO $1.11
- Analyst Decision
- SNGX Strong Buy
- ONFO
- Analyst Count
- SNGX 1
- ONFO 0
- Target Price
- SNGX $6.00
- ONFO N/A
- AVG Volume (30 Days)
- SNGX 659.7K
- ONFO 1.7M
- Earning Date
- SNGX 11-07-2025
- ONFO 11-14-2025
- Dividend Yield
- SNGX N/A
- ONFO N/A
- EPS Growth
- SNGX N/A
- ONFO N/A
- EPS
- SNGX N/A
- ONFO N/A
- Revenue
- SNGX N/A
- ONFO $10,508,728.00
- Revenue This Year
- SNGX N/A
- ONFO N/A
- Revenue Next Year
- SNGX N/A
- ONFO N/A
- P/E Ratio
- SNGX N/A
- ONFO N/A
- Revenue Growth
- SNGX N/A
- ONFO 78.36
- 52 Week Low
- SNGX $1.09
- ONFO $0.61
- 52 Week High
- SNGX $6.23
- ONFO $1.95
- Technical
- Relative Strength Index (RSI)
- SNGX 49.49
- ONFO 51.59
- Support Level
- SNGX $2.58
- ONFO $0.98
- Resistance Level
- SNGX $2.98
- ONFO $1.95
- Average True Range (ATR)
- SNGX 0.19
- ONFO 0.14
- MACD
- SNGX -0.07
- ONFO 0.02
- Stochastic Oscillator
- SNGX 35.94
- ONFO 17.65
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Onfolio LLC.